Recently, Kexing Biopharm (stock code: 688136.SH) , in collaboration with Haichang Biotech, which that its Generic Paclitaxel for Injection (Albumin-bound) has received marketing authorization from the Ministry of Public Health (MSP) of Uruguay.

Bevacizumab's First batch Successfully Shipped to Colombia

On October 13, the "Saudi Arabia (Riyadh)-China (Shenzhen) Medical Device Industry Promotion Conference," themed "Medical Devices Heading to the Gulf, Cooperation Wins the Future," was grandly held in Riyadh, Saudi Arabia.

This year, Kexing Biopharm Co., Ltd. (stock code: 688136.SH), a leading domestic pharmaceutical enterprise in overseas expansion, signed a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd., a renowned innovative enterprise.

On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative product, GB18.

May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care.

Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

Recently, the "Innovation for the World, Exploring for the Future" 2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China), organized by Kexing Biopharm, was successfully concluded in Shanghai.